Abstract: An object of the present invention is to provide a novel method of controlling TYLCV whereby the infection cycle of TYLCV can be broken. The present invention provides a novel virus that is not transmitted by an insect vector as a tomato yellow leaf curl virus. The present invention also provides a method of controlling a tomato yellow leaf curl disease and a method of preventing transmission of a yellow leaf curl virus by using a tomato yellow leaf curl virus not transmitted by an insect vector.

Abstract: The present invention concerns methods and compositions that employ peptides that target dorsal root ganglion (DRG) neurons. In particular, the peptides are used to target therapeutic agents, such as proteins, liposomes, or viral particles comprising therapeutic polynucleotides, to one or more peripheral neuropathies or neuropathic pain, for example. In particular cases, the peripheral neuropathies or neuropathic pain is caused directly or indirectly by DRG neuronopathy.

Abstract: Disclosed are tyrosine-modified rAAV vectors, as well as infectious virions, compositions, and pharmaceutical formulations that comprise them. Also disclosed are methods of preparing and methods for using the disclosed tyrosine-phosphorylated capsid protein mutant rAAV vectors in a variety of diagnostic and therapeutic applications including in vivo and ex vivo gene therapy, and large-scale production of rAAV vectors.

Abstract: Disclosed are improved recombinant adeno-associated viral (rAAV) vectors having mutations in one or more capsid proteins. Exemplary vectors are provided that have altered affinity for heparin or heparin sulfate, as well as vectors, expression systems, and rAAV virions that lack functional VP2 protein expression, but are nevertheless, fully virulent. Also provided by the invention are rAAV vector-based compositions, virus particles, host cells, and pharmaceutical formulations that comprise them useful in the expression of selected therapeutic proteins, polypeptides, peptides, antisense oligonucleotides and/or ribozymes in selected mammals, including organs, tissues, and human host cells.

Abstract: The present invention relates to novel bacteriophages and bacteriophage cocktails containing the novel bacteriophages and or parts and/or products of them, all of them belonging to the Caudovirales order. The novel bacteriophages and the bacteriophage cocktails containing the novel bacteriophages and or parts and/or products of them are Salmonella specific bacteriophages and have lytic activity against Salmonella.

Abstract: The present invention relates to pharmaceutical compositions comprising Avian Paramyxovirus (APMV) for use in the treatment of a tumor in a mammal.

Abstract: The invention relates to a liquid preparation comprising biologically active fungi and/or fungal organs and/or other microorganisms in a suspension, to a method for producing it and to the use thereof for biological protection of plants, for biological plant strengthening, or for biological soil improvement. Polyether-modified trisiloxane is a preferred liquid used. The preparation according to the invention is notable for easily manageable storage at room temperature, trouble-free transport, and simplicity of production and application.

Abstract: This invention relates to the isolation and uses of novel avian astroviruses. The present invention also relates to vaccines, kits and methods for detection of a novel astrovirus. The present invention further relates to vaccination of avians, prevention and/or treatment of avian infections associated with astrovirus. Infections of poultry by this novel astrovirus are associated with runt stunting syndromes.

Abstract: Plant material has bacteriophage has been attached, wherein the bacteriophage retains infectivity. The plant material includes fruits, vegetables, leaves, stems, flowers, roots, tubers, seedlings and seeds. Plant diseases and animal diseases can be treated. A separate composition comprises a carrier selected from (i) a filament, (ii) a planar material, and (iii) particles and/or beads, and bacteriophage covalently attached thereto, wherein the bacteriophage retains infectivity, useful in treatment or prevention of bacterial infection in a deep wound.

Abstract: The present invention relates to a parvovirus for the treatment of mesenchymal tumors, preferably malignant bone tumors such as localized and metastasized bone tumors, in particular osteosarcoma and Ewing's sarcoma. A preferred parvovirus includes a replication competent parvovirus H-1PV.

Abstract: Disclosed are compounds of Formula 1, N-oxides, and salts thereof, wherein X is O or S; Y is O or S; A is O, S, NR3e or C(R3c)?C(R3d); Z is a direct bond, O, S(O)n, NR6, C(R7)2O, OC(R7)2, C(?X1), C(?X1)E, EC(?X1), C(?NOR8) or C(?NN(R6)2); a is 1, 2 or 3; and R1, R2, R3a-R3e, R4, R5, R6, R7, R8, X1 and E are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound or a composition of the invention.

Abstract: The present invention provides duplexed parvovirus vector genomes that are capable under appropriate conditions of forming a double-stranded molecule by intrastrand base-pairing. Also provided are duplexed parvovirus particles comprising the vector genome. Further disclosed are templates and methods for producing the duplexed vector genomes and duplexed parvovirus particles of the invention. Methods of administering these reagents to a cell or subject are also described. Preferably, the parvovirus capsid is an AAV capsid. It is further preferred that the vector genome comprises AAV terminal repeat sequences.

Abstract: The invention relates to a gene transfer-based method to protect a subject from diabetes or obesity. The method comprises administering to a salivary gland of the subject an AAV virion comprising an AAV vector that encodes an exendin-4 protein. Also provided are exendin-4 proteins and nucleic acid molecules that encode such exendin-4 proteins. Also provided are AAV vectors and AAV virions that encode an exendin-4 protein. One embodiment is an exendin-4 protein that is a fusion protein comprising an NGF secretory segment joined to the amino terminus of an exendin-4 protein domain.

Abstract: A method of controlling a deleterious bacteria in oil and gas production, oil and gas completion fluids or other industrial fluids is described which includes identifying a phage capable of infecting the deleterious bacteria, identifying a biocide compatible with the phage and effective against the deleterious bacteria and injecting the biocide and the phage into the oil and gas production, oil and gas completion or other industrial fluid.

Abstract: Medical devices that are resistant to biofilm development and methods of the manufacture of biofilm resistant medical devices are provided. One or more bacteriophages are tethered to the surface of a medical device or a hydrogen-type coating on the surface of the device by covalent bonding while maintaining bacteriophage infective or lytic activity. The presence of the bacteriophages on a medical device, such as an indwelling medical device, prevents biofilm formation or reduces existing biofilm formation on the surface of the device when in use. These devices address the long felt need for biofilm resistant devices that increase safety and reduce complications normally associated with prior indwelling or other medical devices.

Abstract: The present invention comprises rugged, inexpensive, reliable, and sensitive laboratory assays of antibody-based viral neutralization activity and antibody-based viral adherence inhibition activity. The assays use inactivated, fluorescently-labeled virus, allowing the tests to be performed without extensive safety precautions. The interaction of the labeled virus with target cells is monitored using flow cytometric methods. A preferred embodiment uses simple and inexpensive flow cytometry methodologies and equipment, such as bead array readers used as simplified flow cytometers. The assays are rapid, taking no longer than a few hours and are readily conducted by a trained technician. The assays are sensitive because they use labeled viruses at low concentrations and determine neutralizing and blocking capacity of sera and antibody at low concentrations. The methods are appropriate for high-throughput screening of large panels of samples.

Abstract: The present invention is related to a biodegradable carrier with adjustable zeta potentials and particle sizes, a method for making the same, and a pharmaceutical composition comprising the same. In such a method, a first solution comprising a first biodegradable macromolecule is prepared, and a second solution comprising a second biodegradable macromolecule is also prepared according to a desired zeta potential of a biodegradable carrier and further added into the first solution to form a mixture solution. The biodegradable carrier with the desired zeta potentials is formed by the attraction force between the different electric properties. Then, the mole number of the first biodegradable macromolecule and the second biodegradable macromolecule in the mixture solution are proportionally adjusted according to a desired particle size of the biodegradable carrier. Therefore, the zeta potential and the particle size of the biodegradable carrier are adjustable artificially.

Abstract: A method for preventing and treating one or more disease states including the steps of altering the diet of an individual and then administering a drug to the individual. Plasma vitamin C level is reduced from a first level to a second level that is lower than the first level, such that a pharmacological response of the body of the individual to a drug at the first level is different from the pharmacological response of the body of said individual to the drug at the second level.

Abstract: The present invention provides for silk-derived compositions for treating a wide variety of ocular conditions. The composition is produced by processing the silk cocoon into a water-based solution (i.e., a dissolved silk), which is then cast into a film. The film may be transparent to visible light, and curved in shape for easy application to the ocular surface. The silk film may either self-adhere or be sutured to cover the wound. The degradation time of the film may range from 1 minute to 24 hours, or from 2 hours to 20 hours. The present compositions can help regenerate damaged corneal tissue, thus promoting healing.

Abstract: The present invention relates to a novel bacteriophage, more particularly, a bacteriophage that has a specific bactericidal activity against Salmonella typhimurium, Salmonella gallinarum, or Salmonella pullorum, a composition for the prevention or treatment of infectious diseases including salmonellosis and Salmonella food poisoning caused by Salmonella typhimurium, Fowl typhoid caused by Salmonella gallinarum, and Pullorum disease caused by Salmonella pullorum, which comprises the bacteriophage as an active ingredient, and an animal feed, drinking water, cleaner, and sanitizer which comprise the bacteriophage as an active ingredient. The present invention also provides important insights into prevention and control strategies against Salmonella infection and suggests that the use of bacteriophage can be a novel, safe, and effectively plausible alternative to antibiotics for the prevention of Salmonella infection in poultry.

Abstract: Recombinant strains of avian paramyxovirus (APMV), such as Newcastle disease virus (NDV), are provided. Also provided are compositions comprising them, and methods of using them to lyse tumor cells and to treat cancer. In certain aspects, genetically-engineered viral strains that incorporate therapeutic transgenes are also provided. The recombinant viruses may be used in accordance with methods of providing enhanced oncolytic efficacy and delivering an oncolytic virus to tumors present in a patient. Also provided are methods for identifying a recombinant virus as an oncolytically-effective agent.

Abstract: The present invention relates, in general, to attenuated negative-strand RNA viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. The invention also relates to the development and use of IFN-deficient systems for selection of such attenuated viruses. In particular, the invention relates to attenuated influenza viruses having modifications to the NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. The mutant viruses replicate in vivo but demonstrate reduced pathogenicity, and therefore are well suited for live virus vaccines, and pharmaceutical formulations.

Abstract: Systems and methods for magnetic targeting of therapeutic particles are provided. Therapeutic particles comprise one or more magnetic or magnetizable materials and at least one therapeutic agent. Therapeutic particles are specifically targeted using uniform magnetic fields capable of magnetizing magnetizable materials, and can be targeted to particular locations in the body, or can be targeted for capture, containment, and removal. Also provided are bioresorbable nanoparticles prepared without the use of organic solvents, and methods for therapeutically using such bioresorbable nanoparticles.

Abstract: Disclosed are compositions and methods useful for targeting therapeutics to cancerous cells and tumors. The disclosed targeting is useful for delivering therapeutic and detectable agents to cancerous cells and tumors.

Abstract: Embodiments of the invention are directed methods that include a thymidine kinase deficient vaccinia virus. The methods include evaluating a tumor for reperfusion after treatment with vaccinia virus and administering an anti-angiogenic agent if reperfusion is detected.

Abstract: The invention relates to a gene transfer-based method to protect a subject from Sjogren's syndrome. The method comprises administering to the subject an AAV virion comprising an AAV vector that encodes a soluble CTLA-4 (sCTLA-4) protein. Also provided are sCTLA-4 proteins and nucleic acid molecules that encode such sCTLA-4 proteins. Also provided are AAV vectors and AAV virions that encode a sCTLA-4 protein.

Abstract: The present invention provides methods for development of a virulent bacteriophage-based treatment for the control of plant diseases caused by Xylella fastidiosa. The invention further provides methods of isolating and propagating bacteriophage virulent to X. fastidiosa in a Xanthomonas bacterial host and for treating or reducing symptoms of X. fastidiosa infection in a plant. The invention further provides methods of isolating and propagating bacteriophage virulent to Xanthomonas axonopodis pv. citri and for treating or reducing symptoms of Xanthomonas axonopodis pv. citri infection in a plant.

Abstract: The invention provides compositions and methods for making and using modified viruses, including infectious viruses, having an external surface linked to at least one heterologous unnatural moiety that is exemplified by unnatural amino acid and unnatural saccharide. The unnatural moiety that is linked to the invention's modified viruses is optionally further linked to a molecule of interest (such as probe, cytotoxin, therapeutic molecule, antibody, affibody, epitope, etc. The invention's compositions and methods for use in, for example, diagnostic applications and therapeutic applications such as gene therapy, oncolytic therapy, and/or vaccine therapy.

Abstract: The present invention relates to compositions of virus-like particles for the introduction of RNA-interference (RNAi-) inducing molecules into eukaryotic cells and methods for the cell type-specific transduction of a plurality of eukaryotic cells with RNAi-inducing molecules. The present invention furthermore relates to methods for a diagnosis, prevention and/or treatment of diseases or disease states associated with an increased expression rate of at least one endogenous gene, and/or with the undesired expression of at least one endogenous gene and/or foreign nucleic acids, in particular viral nucleic acids.

Abstract: The invention provides compositions for inducing expression in hair cells, and provides methods of using these compositions for modulating cochlear expression. Such compositions are further useful in treatment of sensorineural hearing loss, e.g., increasing proliferation or survival of mechanosensory hair cells.

Abstract: The present invention relates to therapeutic use of a combination of Myxoma virus, including in combination with rapamycin. Treatment with rapamycin enhances the ability of Myxoma virus to selectively infect cells that have a deficient innate anti-viral response, including cells that are not responsive to interferon. The combination of rapamycin and Myxoma virus can be used to treat diseases characterized by the presence of such cells, including cancer. The invention also relates to therapeutic use of Myxoma virus that does not express functional M135R.

Abstract: There is a disclosed a method of killing abnormal cells such as malignant cells including melanoma cells, using a virus recognising at least one of a cell adhesion molecule and a complement regulatory protein. The virus may be a member of the Picornaviridae family. Coxsackie A-group viruses have been found to be particularly suitable. The cell adhesion molecule is desirably a member of the immunoglobulin (Ig) superfamily. Typically, the complement regulatory protein will be DAF.

Abstract: This disclosure provides modified cytosine deaminases (CDs). The disclosure further relates to cells and vector expressing or comprising such modified CDs and methods of using such modified CDs in the treatment of disease and disorders.

Abstract: Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N-oxides, and salts thereof, wherein A is a 6-membered aromatic ring containing carbon atoms and 0-3 nitrogen atoms as ring members, said ring optionally substituted with 1-5 substituents independently selected from R2; R1 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C7 alkylcycloalkyl or C4-C7 cycloalkylalkyl, each optionally substituted with one or more substituents independently selected from R21; R21 is independently H, halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C1-C6 alkylsulfinyl, C1-C6 haloalkylsulfinyl, C1-C6 alkylsulfonyl, C1-C6 haloalkylsulfonyl, CN or NO2; and Q is as defined in the disclosure.

Abstract: The invention relates to a polypeptide, a corresponding nucleic acid molecule, a construct and/or vector and/or cell comprising such nucleic acid molecule and/or a composition comprising said polypeptide, nucleic acid molecule, construct, vector and/or cell. The invention further relates to such composition for medical use, preferably for use in treating an infectious disease. Furthermore, the invention relates to the use of said polypeptide, nucleic acid molecule, construct, vector, cell and/or composition as an antimicrobial, preferably as a food additive or disinfectant, or for detecting bacteria, preferably in a diagnostic application.

Abstract: This invention discloses a novel method for propagation of viral vectors encoding proteins that induce apoptosis. The invention also discloses viral vectors produced by such methods and cells transfected with such vectors. Also disclosed are methods for suppressing T-lymphocyte-mediated graft rejection, for suppressing T-lymphocyte-mediated disease and for inducing apoptosis in cancer cells.

Abstract: Disclosed are suspension concentrate compositions comprising by weight based on the total weight of the composition, (a) from about 0.1 to about 50% of one or more carboxamide arthropodicides that are solid at room temperature; ( b) from 0 to about 50% of one or more biologically active agents other than the carboxamide arthropodicides; (c) from about 20 to about 70% of water; (d) from about 10 to about 70% of one or more water-immiscible liquid compounds; and (e) from about 1 to about 55% of a surfactant component having a dispersing property. This invention also relates to a method for controlling an arthropod pest comprising diluting said suspension concentrate composition with water, optionally adding an adjuvant to form a diluted composition, and contacting the arthropod pest or its environment with an effective amount of said diluted composition.

Abstract: A combination comprising an enaminocarbonyl compound of formula (I): wherein R is methyl, cyclopropyl or 2,2-difluoroethyl, and at least one biological control agent selected from bacteria, fungi or yeasts, protozoas, viruses, and entomopathogenic nematodes, and optionally an inoculant, for reducing overall damage of plants and plant parts as well as losses in harvested fruits or vegetables caused by insects, mites nematodes and phytopathogens.

Abstract: A method of co-expressing a portion of the VSV G protein gene or a truncated “stem” portion with GP64 and a retrovirus increases the titer of retroviral vectors. A truncated VSV G protein, preferably comprised of a small segment from the C-terminal portion of the ectodomain plus the transmembrane (TM) and cytoplasmic tail (CTD) domains of VSV G, co-expressed with retroviral vectors, enhances the production titers of the retroviral vectors. A preferred embodiment uses a VSV G construct that includes an N-terminal c-Myc epitope plus 42 amino acids from the C-terminal portion of the ectodomain, 20 amino acids from the predicted TM domain, and 29 amino acids from the predicted CTD of the VSV G protein.

Abstract: An isolated strain of bacteriophage, specific against bacteria belonging to the Vibrio genre, particularly the anguillarum species, deposited on 3 Oct. 2012 at the Polish Collection of Microorganisms (PCM) of the Ludwik Hirszfeld Institute of Immunology and Experimental Therapy of the Polish Academy of Sciences, with access number F/00072, characterized in that said strain is efficient in the prophylaxis, control and/or treatment of the infection caused by Vibrio anguillarum in all types of species of fish, mollusks and crustaceans that are important for aquaculture susceptible to this bacteria, genome size 48.6 Kb, it is not sensitive to chloroform and its storage temperature is ?80° C.

Abstract: Provided is a modified bacteriophage capable of infecting a target bacterium, which bacteriophage includes an ?/? small acid-soluble spore protein (SASP) gene encoding a SASP which is toxic to the target bacterium, wherein the SASP gene is under the control of a constitutive promoter which is foreign to the bacteriophage and the SASP gene.

Abstract: The invention relates to a composition which, depending on the user, may be taken as a nutritional, dietetic or strictly therapeutic preparation, comprising as its active substance alkaline sphingomyelinase which is capable of preventing or treating various pathological conditions including cancerous processes, inflammatory processes of the intestine, hypercholesterolaemia and infections with Helicobacter pylori.

Abstract: Disclosed are compositions comprising (a) at least one compound selected from compounds of Formula 1, N-oxides, and salt thereof, wherein R1 is phenyl optionally substituted with up to 5 substituents independently selected from R3, or pyridinyl optionally substituted with up to 4 substituents independently selected from R3; R2 is C1-C4 haloalkyl; or thiazolyl, pyridinyl or pyrimidinyl, each optionally substituted with up to 2 substituents independently selected from the group consisting of halogen and C1-C4 alkyl; each R3 is independently halogen, cyano, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C(R4)?NOR4 or Q; each R4 is independently C1-C4 alkyl; Z is CH?CH or S; and each Q is independently phenyl or pyridinyl, each optionally substituted with up to 3 substituents independently selected from the group consisting of halogen, cyano, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy and C1-C4 haloalkoxy; and (b) at least one invertebrate pest control agent.

Abstract: The invention relates to virology and the prevention and/or treatment of viral infection and disease in animals, including birds and humans. The invention relates to the field of antiviral treatments. The invention further relates to methods of stimulating innate immunity and natural interferon production in humans or animals and in component parts of humans or animals, including cells and tissues. The invention also relates to the field of defective interfering (DI) viruses, including cloned DI viruses.

Abstract: The present invention provides an amphiphilic linear peptide and/or peptoid as well as a hydrogel that includes the amphiphilic linear peptide/peptoid.

Abstract: The present invention relates to a novel, isolated and purified hemorrhagic feline calicivirus FCV-DD1. The invention further embraces monovalent and multivalent vaccines containing the new FCV-DD1 strain. In addition, the invention encompasses methods of protecting felines against infection or preventing disease caused by feline calicivirus alone or in addition to other pathogens that comprises administering to the felines an immunologically effective amount of the monovalent and multivalent vaccines described herein. Also, the invention concerns methods for diagnosing or detecting the hemorrhagic feline calicivirus in a susceptible host, asymptomatic carrier and the like by detecting the presence of feline calicivirus FCV-DD1 or antibodies raised or produced against feline calicivirus FCV-DD1 antigen.

Abstract: The invention relates to a method for producing a mixture of bacteriophages, wherein at least two different bacteriophage strains have been reproduced separately, wherein a staphylococcus strain is grown in an preculture with each of strains of a bacteriophage that can lyse staphylococci and is then further reproduced in a main culture, and is then purified, and the different strains are then mixed, wherein the mixture of bacteriophages used comprises at least two different serotypes of bacteriophages that lyse specifically bacteria of the species Staphylococcus.

Abstract: The present invention is directed to a filamentous bacteriophage for use in treating a neurodegenerative tauopathy or susceptibility to a neurodegenerative tauopathy and a method of using the bacteriophage for reducing the formation of fibrils of tau protein or for disaggregating pre-formed fibrils of tau protein, such as in a patient suffering from neurodegenerative tauopathy. The filamentous bacteriophage used in the present invention does not display (i) a mammalian cell internalization signal (ii) a ?-amyloid antigen or an antibody to ?-amyloid, or (iii) a tau protein antigen or an antibody to tau protein.

Abstract: Provided herein are compositions containing a vaccinia virus and a protein polymer, and articles of manufacture thereof. Also provided are diagnostic and therapeutic methods using the compositions or articles of manufacture.

Abstract: Disclosed herein are UV-resistant gelatin/silica coated viral particles, methods for producing the same, and methods for controlling agricultural insect pests using the UV-resistant gelatin/silica coated viral particles.